Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Serum osteopontin as a prognostic marker in patients with lung cancer

Vasiliki Petta, Stelios Loukides, Konstantinos Kostikas, Georgios Papatheodorou, Kyriaki Cholidou, Yiannis Tomos, Spyridon Papiris, Nikolaos Koulouris, Petros Bakakos
European Respiratory Journal 2015 46: PA4246; DOI: 10.1183/13993003.congress-2015.PA4246
Vasiliki Petta
11st Respiratory Medicine Department, Sotiria General Hospital, University of Athens Medical School, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stelios Loukides
22nd Respiratory Medicine Department, Attiko Hospital, University of Athens Medical School, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantinos Kostikas
32nd Respiratory Medicine Department, Attiko Hospital, University of Athens Medical School, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgios Papatheodorou
4Microbiology Department, 401 Military Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyriaki Cholidou
51st Respiratory Medicine Department, Sotiria General Hospital, University of Athens Medical School, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiannis Tomos
62nd Respiratory Medicine Department, Attiko Hospital, University of Athens Medical School, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spyridon Papiris
72nd Respiratory Medicine Department, Attiko Hospital, University of Athens Medical School, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolaos Koulouris
81st Respiratory Medicine Department, Sotiria General Hospital, University of Athens Medical School, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petros Bakakos
91st Respiratory Medicine Department, Sotiria General Hospital, University of Athens Medical School, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: Osteopontin (OPN) is a multifunctional cytokine that has been involved in cancer development, angiogenesis and metastasis. OPN is overexpressed in lung cancer and it has been evaluated as a biomarker of its progression. Increased OPN sputum levels have been detected in patients with COPD. Lung cancer (LC) and COPD are both smoking-related diseases and may share common pathogenetic mechanisms.

Objective: We measured serum levels of OPN in patients with LC with and without coexistent COPD in order to evaluate its prognostic performance on 1-year mortality.

Methods: We recruited 167 patients with LC, mean age 66±10 years, 119 current smokers, 85 with concomitant COPD, whereas 20 patients with COPD served as a control group. All subjects underwent lung function tests and serum collection for OPN measurement. All patients were optimally treated for LC and COPD according to their attending physicians and were followed for one year or until death.

Results: Patients with LC (with or without concomitant COPD) presented higher serum OPN levels compared to those with COPD alone [median IQR 36 (23-54) vs 45 (24-69) vs 27(15-34) ng/ml respectively, p=0.006]. No significant difference was observed in serum OPN between the LC groups (with and without COPD, p=0.171). In multivariate Cox regression analysis, serum OPN > 50ng/ml was an independent predictor of 1-year mortality (HR 3.014 95% CI 1.821-5.130). SCLC was another significant predictor of 1-year mortality compared to NSCLC. (HR 1.19 95% CI 0.86-1.3).

Conclusion: Serum OPN with a cut-off value of 50ng/ml could predict 1-year mortality in patients with lung cancer. The co-existence of COPD did not seem to affect its prognostic value.

  • Lung cancer / Oncology
  • Biomarkers
  • COPD - mechanism
  • Copyright ©ERS 2015
Previous
Back to top
Vol 46 Issue suppl 59 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Serum osteopontin as a prognostic marker in patients with lung cancer
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Serum osteopontin as a prognostic marker in patients with lung cancer
Vasiliki Petta, Stelios Loukides, Konstantinos Kostikas, Georgios Papatheodorou, Kyriaki Cholidou, Yiannis Tomos, Spyridon Papiris, Nikolaos Koulouris, Petros Bakakos
European Respiratory Journal Sep 2015, 46 (suppl 59) PA4246; DOI: 10.1183/13993003.congress-2015.PA4246

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Serum osteopontin as a prognostic marker in patients with lung cancer
Vasiliki Petta, Stelios Loukides, Konstantinos Kostikas, Georgios Papatheodorou, Kyriaki Cholidou, Yiannis Tomos, Spyridon Papiris, Nikolaos Koulouris, Petros Bakakos
European Respiratory Journal Sep 2015, 46 (suppl 59) PA4246; DOI: 10.1183/13993003.congress-2015.PA4246
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
  • Risk factors of febrile neutropenia induced by chemotherapy in lung cancer patients
  • Evaluation of response to chemotherapy with fiberoptic bronchoscopy in lung cancers
Show more 11.1 Lung Cancer

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society